重药控股(000950.SZ):盐酸普拉格雷片临床试验获受理

智通财经网
Jun 24, 2025

重药控股(000950.SZ)公告,公司控股子公司重庆医药(集团)股份有限公司(简称“重药股份”)收到国家药品监督管理局签发的《受理通知书》,药物名称为:盐酸普拉格雷片。

公告显示,盐酸普拉格雷片原研公司为第一三共株式会社,是第三代的抑制ADP激活的血小板聚集的药物,适应于预防接受经皮冠状动脉介入治疗后的急性冠状动脉综合征、稳定型心绞痛,陈旧性心肌梗塞患者的血栓形成。

海量资讯、精准解读,尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10